price jan usd
strengthen convict above-
buy rate reect view compani continu exceed
market growth rate despit uniqu challeng comp result
organ growth well exceed expect support view
thing like
strong organ sale growth beat organ sale growth
meaning outpac dbe consensu print
even impress light tough prior year compar
compani face out-performance across segment drove upsid
analyt instrument growth vs prior yr compar
notabl
growth guid contempl macro risk ep guid better
optic suggest organ sale growth guidanc
contempl wide rang end market growth outcom light
sever macro risk brexit european slowdown china tari
well dicult growth comparison said underli
market trend remain healthi see room upsid guidanc
trend maintain adjust ep guidanc rang look
uninspir rst glanc mid-point fall well consensu
estim per bloomberg said exclud
dilut relat anatom patholog busi divestitur
mid-point much closer consensu forecast addit
exclud increment ep headwind relat china tari
put mid-point consensu though sure
consensu includ relat increment tari impact
biopharma end market sale grew low-teen rang driven
strength across busi notabl pharma servic
biopharma growth driven continu end market health well
china growth remain robust china sale growth healthi
manag note persist strength order growth
good pace dec-end quarter consolid
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
growth guidanc assum china sale growth deceler modestli
mid-teen rang
thing cautiou
oper margin miss forecast adjust oper margin
om came well forecast compani
ramp strateg invest spend quarter look
forward expect adjust om expand basi point
bp quarter despit bp headwind china tari
divestitur anatom patholog busi expect
rais pt
rais price target reect roll forward
valuat framework price target reect enterpris valu
use project level debt cash trail twelv
month ebitda ex option forecast multipl premium ev/ftm
ebitda multipl think warrant multipl
in-lin ev/ftm ebitda multipl life scienc tool diagnost
forecast ratio
period end incom expens expens incom continu share share ep dilut cont sale excl acquir intang cash flowoperar cash cash revenu
period end equival short-term current equip intang asset sharehold equitynot payabl current matur lt current liabil sharehold equiti minor januari
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/
research/disclosures/companysearch asid within report import risk conict disclosur also found http //research db com/research/topics/equ
